• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Catalent to acquire Pharmatek

Catalent to acquire Pharmatek

September 15, 2016
CenterWatch Staff

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced an agreement for Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, to acquire Pharmatek Laboratories, a West Coast, U.S.-based specialist in drug development and clinical manufacturing.

The acquisition will add extensive early-phase drug development capabilities from discovery to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds. The addition of spray drying will also provide Catalent customers with a comprehensive suite of bioavailability enhancement solutions, while complementing and expanding Catalent’s OptiForm Solution Suite platform, a science-driven parallel screening approach to identify the optimal formulation pathway for poorly soluble compounds. No financial details have been disclosed.

Founded in 1999, Pharmatek provides dosage form development and clinical-scale cGMP manufacturing of oral, injectable and topical products for more than 100 customers globally. At its San Diego facility, Pharmatek offers a fully integrated drug development platform, with discovery formulation screening for lead selection and optimization, comprehensive formulation development and analytical services, and finished dose form manufacturing for clinical supply. Additional services include first-in-man strategies, solutions for poorly soluble compounds, controlled release formulations, and specialized facilities and controls for potent compound handling.

“Catalent continues to expand its industry-leading drug development and delivery technologies to help its pharmaceutical partners to fully unlock the potential of their molecules and provide better treatments for patients,” said Barry Littlejohns, president of Catalent’s Drug Delivery Solutions business. He added, “Combined with Catalent’s existing technologies and network, the addition of Pharmatek’s well-established scientific expertise and spray dry capabilities will create an unparalleled drug development platform, while the San Diego facility will expand our West Coast presence and provides additional access to the Asia-Pacific markets.”

Pharmatek’s site in San Diego is a cGMP facility that employs nearly 200 people, whose experience and expertise will complement Catalent’s existing development and analytical services teams, based at multiple locations globally. Pharmatek provides development and analytical services for more than 120 molecules annually, and its facility comprises 68,000 square feet of laboratory, manufacturing and support space, with 2 analytical labs, 2 formulation labs, 4 engineering rooms and 9 Certified ISO Class 8 manufacturing suites. The site also features 18,000 square feet of laboratory, manufacturing and support space dedicated to development and manufacturing of highly-potent compounds.

The transaction is subject to customary closing conditions and is expected to close in the next few weeks.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing